Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.

导出 OA

翻译打印收藏纠错

作者： Britta,Vormoor ^[1] ; Yvonne T,Schlosser ^[2] ; Helen,Blair ^[3] ; Abhishek,Sharma ^[1] ; Sarah,Wilkinson ^[4] ; David R,Newell ^[5] ; Nicola,Curtin ^[6]

作者单位： Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. ^[1] Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. ^[2] German Cancer Research Center, DKFZ, Cell Cycle Control and Carcinogenesis, Heidelberg, Germany. ^[3] NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg. ^[4] Northumbria University, Department of Health and Life Sciences, Newcastle upon Tyne, UK. ^[5] Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Newcastle upon Tyne, UK. ^[6]

关键词 DNA-PK inhibitor NU7441 PARP-inhibitor ewing sarcoma rucaparib

DOI 10.18632/oncotarget.21300

PMID 29371919

发布时间 2022-03-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交